Onkologie. 2024:18(4):249-253 | DOI: 10.36290/xon.2024.051

Her2 positive metastatic gastric cancer

Marián Liberko^{1, 2}, Renata Soumarová^{1, 2}

¹ Onkologická klinika, 3. LF UK a FNKV, Praha

² 3. lékařská fakulta Univerzity Karlovy, Praha

Her2 positive metastatic gastric cancer is diagnosed in approximately 20% of patients. For more than a decade, palliative chemotherapy in combination with the anti-Her2 agent, trastuzumab, has been the standard of care for these patients. Numerous efforts to introduce additional anti-Her2 agents into the treatment algorithm for metastatic disease have been unsuccessful. It is only in recent years that a better understanding of tumour biology has led to a shift in this field, with rational combinations of agents and new molecules. The aim of this article is to provide an overview of pivotal studies on Her2-positive metastatic disease, including the most recent ones that are leading to improved therapeutic outcomes after years of stagnation.

Keywords: Her2 positivity, metastatic gastric cancer, trastuzumab, immunotherapy, antibody-drug conjugate.

Accepted: October 1, 2024; Published: October 7, 2024  Show citation